

# Heart Failure Warning Strengthened for TZDs

BY ELIZABETH MECHCATIE  
Senior Writer

The labels of all thiazolidinediones now carry a black box warning about the risk of heart failure, the Food and Drug Administration announced on Aug. 14.

The strengthened warning emphasizes that thiazolidinediones (TZDs) may “cause or exacerbate congestive heart failure in some patients,” according to the FDA.

The agency sent the manufacturers letters requesting the labeling change in May. Product labeling for the TZDs rosiglitazone (Avandia), manufactured by Glaxo-SmithKline, and pioglitazone (Actos), manufactured by Takeda, previously contained information about heart failure (HF) in the warnings and precautions sections, but the labeling is being strengthened following recent revelations about rosiglitazone’s cardiovascular safety.

The FDA says that the concern over heart failure is “separate” from the concerns over the increased MI risk associated with rosiglitazone, which was the subject of a joint meeting of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee in July.

The committees concluded then that data from meta-analyses of the rosiglitazone clinical program show an increased risk for myocardial ischemia for the type 2 diabetes therapy. The agency is currently reviewing similar pooled data from the pioglitazone clinical program.

“This new boxed warning addresses FDA’s concerns that despite the warnings and information already listed in the drug labels, these drugs are still being prescribed to patients without careful monitoring for signs of heart failure,” Dr. Steven Galson, director of the FDA’s Center for Drug Evaluation and Research, said in a statement.

“The strengthened warning advises health care professionals to observe patients carefully for the signs and symptoms of heart failure, including excessive, rapid weight gain, shortness of breath, and edema after starting drug therapy,” according to the FDA.

The updated labeling states that initiation of rosiglitazone or pioglitazone is contraindicated in patients with New York Heart Association class III or IV heart failure. After treatment with these products is initiated or if the dose is increased, patients should be observed for signs of heart failure. If a patient is diagnosed with heart failure, discontinuation or dose reduction of the TZD “should be considered.”

The rosiglitazone data cited by the FDA include a year-long echocardiographic study in type 2 diabetic patients with NYHA class I or II heart failure, who were receiving treatment for diabetes and HF; the study did not find treatment-related differences in the change from baseline in ejection fraction. But the risk of heart failure exacerbations was higher in patients on rosiglitazone (6%), compared with those on placebo (4%). In addition, the rates of worsening edema, worsening dyspnea, and increases in heart failure medications were

higher among those on rosiglitazone (25%, 26%, and 33%, respectively), compared with those on placebo (9%, 17%, and 18%).

Among the pioglitazone data cited by the FDA was a 24-week study comparing the TZD to glyburide in 518 patients with NYHA class II and III heart failure and an ejection fraction below 40%. In the study, overnight hospitalizations for heart failure were reported in nearly 10% of those on pioglitazone, compared with almost 5% of those on glyburide, an adverse event that

was “more marked” in patients taking insulin at baseline and in those older than age 64.

The label revision also extends to the combination products that include the TZDs: Avandaryl (rosiglitazone and glimepiride), Avandamet (rosiglitazone and metformin), and Duetact (pioglitazone and glimepiride).

The FDA is continuing to monitor post-marketing reports of heart failure; its review of rosiglitazone and the possible in-

creased risk of MI also is ongoing. ■

For more information, go to: [www.fda.gov/medwatch/safety/2007/safety07.htm#rosi\\_pio](http://www.fda.gov/medwatch/safety/2007/safety07.htm#rosi_pio). Adverse or serious events associated with TZDs should be reported to the FDA’s MedWatch program at [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

Brian Marson, assistant news editor for Elsevier’s “The Pink Sheet,” contributed to this report.



**Discover Levemir®:**  
a long-acting basal insulin  
with a light touch

Levemir: for your patients who need a safe and effective way to improve A1C control

With proven reductions in A1C and FPG levels over time, Levemir can help your patients get to goal with up to 24 hours of glycemic control. Patients with diabetes can experience a consistent blood glucose response from injection to injection. Less weight gain was observed with Levemir in 12 of 12 clinical trials.\* And Levemir is available in the Levemir® FlexPen®, FlexPen® is the world’s #1 selling prefilled insulin pen.† So start your patients with diabetes on Levemir, and help them experience the light side of basal insulin.

Levemir is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

**Important safety information**  
Levemir should not be diluted or mixed with any other insulin preparations.  
Levemir is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.  
Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin dose should be made cautiously

and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.  
Levemir is not to be used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir from other intermediate or long-acting insulin preparations. The dose of Levemir may need to be adjusted in patients with renal or hepatic impairment.  
Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients

in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.  
\*Whether these observed differences represent true differences in the effects of Levemir and NPH insulin is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.



**Levemir®**  
insulin detemir (rDNA origin) injection  
Lighter years ahead

 Reference: 1. IMS Health, IMS MIDAS [12 months ending September 2005].  
Please see brief summary of Prescribing Information on adjacent page.  
FlexPen and Levemir are registered trademarks of Novo Nordisk A/S.  
© 2006 Novo Nordisk Inc. 131007 September 2006